Roslyn E. Wallace

Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones

K. C. Murdock, Ralph G. Child, P. F. FABIO et al. · Journal of Medicinal Chemistry · 1979 · 283 citations

Medicinal Chemistry, Antitumor Agents, Medicine +10

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

James P Buteau, Andrew Martin, Louise Emmett et al. · The Lancet Oncology · 2022 · 239 citations

Biomarker (Medicine), Prognostic Biomarkers, Urology +7

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 172 citations

Urology, Overall Survival, Genitourinary Cancer +8

Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis(((2-[(2-hydroxyethyl)amino]ethyl)amino])-9,10-anthracenedione dihydrochloride, against experimental tumors in mice.

Roslyn E. Wallace, K. C. Murdock, Robert B. Angier et al. · PubMed · 1979 · 149 citations

Chemoprevention Strategy, Immunology, Metronomic Chemotherapy +18

Development and characerization of cell lines from subhuman primates

Roslyn E. Wallace, P. J. Vasington, John C. Petricciani et al. · In Vitro Cellular & Developmental Biology - Plant · 1973 · 57 citations · Full text

Developmental Biology, Cell Lines, Morphogenesis +4